Targeted Deep Sequencing Method Detects Rare Mutations in Circulating Tumor DNA | GenomeWeb

Researchers in the UK have developed a targeted sequencing approach to detect mutations in circulating tumor DNA that they believe could eventually be developed as a clinical assay for early cancer diagnosis or to monitor disease progression and treatment response.

Their strategy, tagged-amplicon deep sequencing, or TAm-Seq, is a two-step amplification process that combines the Fluidigm Access Array with Illumina sequencing.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: map of UV-induced damage in yeast genome, comparative epigenomics uncovers plant lacking key DNA methyltransferase enzyme, and more.

Researchers kick off their second Queer in STEM survey to examine what can make STEM careers welcoming, Wired reports.

A startup company is offering a test to analyze soil samples from farms for pathogens.

Prosecutors seek to introduce evidence from low-template DNA analysis in a murder case in upstate New York, the New York Times reports.